Mitglieder der German Breast Group präsentierten im Jahr 2012 folgende Beiträge auf internationalen Kongressen:
Martin M, Loibl S, von Minckwitz G, Morales S, Crespo C, Anton A, Guerrero A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JA, Gil M,Ramos M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba J R: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - First efficacy results from the LEA study. Cancer Res 72 (24 Suppl.): 91s, 2012
Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M: Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial. Cancer Res 72 (24 Suppl.): 95s, 2012
Loibl S, Jackisch C, Gade S, Untch M, Paepke S, Kuemmel S, Schneeweiss A, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B,Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Nekljudova V, Mehta K, von Minckwitz G: Neoadjuvant chemotherapy in the very young 35 years of age or younger. Cancer Res 72 (24 Suppl.): 96s, 2012
Denkert C. Blohmer JU, Müller BM, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Budczies J, Erbstößer E, Loibl S, von Minckwitz G: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial. Cancer Res 72 (24 Suppl.): 102s, 2012
Klauschen F, Wienert S, Blohmer J-U, Mueller BM, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Erbstoesser E, Loibl S, Denkert C, von Minckwitz G: Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort. Cancer Res 72 (24 Suppl.): 33s, 2012
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer J-U, Costa S-D, Jackisch C, Paepke S, Schneeweiss A, Kuemmel S, Denkert C, Mehta K, Untch M: Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Res 72 (24 Suppl.): 15s, 2012
Untch M, Prinzler J, Fasching P, Müller BM, Gade S, Meinhold-Heerlein I, Huober J, Karn T, Liedtke C, Loibl S, Müller V, Rack B, Schem C, Darb-Esfahani S, von Minckwitz G, Denkert C: Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial. Cancer Res 72 (24 Suppl.): 36s, 2012
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S: Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial. Cancer Res 72 (24 Suppl.): 71s, 2012
Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G: Dual blockade with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70. Cancer Res 72 (24 Suppl.): 18s, 2012
Linder M, von Minckwitz G, Kamischke A, Rudolwski C, Eggemann H, Nekljudova V, Loibl S: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE). Cancer Res 72 (24 Suppl.): 43s, 2012
Untch M, Jackisch C, Blohmer J-U, Costa S-D, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Kuemmel S, Schneeweiss A, Paepke S, Loibl S, Nekljudova V, von Minckwitz G: A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) GBG 69. Cancer Res 72 (24 Suppl.): 67s, 2012
Thomssen C, Kantelhardt EJ, Meisner C, Vetter M, Schmidt M, Martin P-M, Veyret C, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jaenicke F, von Minckwitz G, Harbeck N: First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients. Cancer Res 72 (24 Suppl.): 15s, 2012
Ataseven B, Blohmer J.U, Denkert C BeGerber B, Heil J, Kühn T, Kümmel S, Rezai M, Loibl S, von Minckwitz G for the GBG and AGO-B Study Groups: Impact of multifocal or multicentric disease on surgical, locoregional, and distant survival after neoadjuvant chemotherapy in 3562 breast cancer patients. Annals of Oncology Volume 23 (Supplement 9), 117, 2012
Loibl S, De la Haba J, von Minckwitz G, Morales S, Crespo C, Antón A, Carrasco E, Aktas B, Mehta K, Martin M: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - Safety Analysis LEA study. Annals of Oncology Volume 23 (Supplement 9), 118, 2012
von Minckwitz G, Mueller B, Blohmer J.U, Kaufmann M, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Ruediger T, Erbstoesser E, Loibl S, Denkert C: Prognostic and predictive impact of Ki-67 before and after neoadjuvant chemotherapy on PCR and survival: Results of the GeparTrio trial. J Clin Oncol 30, (suppl; abstr 1023), 2012
Huober J, Denkert C, Minckwitz G, Prinzler J, Kronenwett R, Darb-Esfahani S, Mehta K, Sinn B.V, Untch M, Loibl S: Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. J Clin Oncol 30, (suppl; abstr 523), 2012
Maass N, Harbeck N, Mundhenke C, Lerchenmuller C, Barinoff J, Lueck H.J, Ettl J, Aktas B, Kuemmel S, Roesel S, Wagner S, Müller L, Bischoff J, Luebbe K, Schwedler K, Schmidt M, Bauerschlag D, Nekljudova V, Loibl S, von Minckwitz G: Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study. J Clin Oncol 30, (suppl; abstr 556), 2012
Pirvulescu C, Loibl S, von Minckwitz G, Mau C, Blohmer J.U, Dan Costa S, Eidtmann H, Fasching P.A, Gerber B, Untch M: Response pattern in 844 patients with infiltrating lobular carcinoma (ILC) of the breast after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 541), 2012
Sinn B.V, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H.J, Mehta K, Loibl S: Mucin-1 protein and mRNA expression in breast cancer: Predictive value for therapy response and survival after neoadjuvant chemotherapy. J Clin Oncol 30, (suppl; abstr 522), 2012
Harbeck N, Maass N, Mundhenke C, Lerchenmüller C, Barinoff J, Etti J, Aktas B, Nekljudova V, von Minckwitz, Loibl S: Everolimus (Rad001) as Treatment in Breast Cancer Patients with Bone Metastases Only – First Results of the Multi-centre, Placebo-controlled, Randomized Discontinuation Phase II RADAR Study. European Journal of Cancer Vol. 48, Supplement 1, S43, 2012
Loibl S, von Minckwitz G, Kaufmann M: Adjuvant hormone therapy following primary therapy for endometrial cancer Preview. European Journal of Cancer Vol. 38, Supplement 6, 41-43, 2012
von Minckwitz G, Steffen J, Wiest W, Thomssen C, Augustin D, Conrad B, Wesenberg B, Wittenberg M, Loibl S: Patient Self-reported Outcome for Long-term Follow up of Early Breast Cancer Trials. European Journal of Cancer Vol. 48, Supplement 1, S52, 2012
Loibl S, Gerber B: Managing adverse effects of treatment – Fertility. European Journal of Cancer Vol. 48, Supplement 1, S101, 2012
Loibl S: Breast Cancer in the Young. European Journal of Cancer Vol. 48, Supplement 1, S45, 2012